MTFB Motif Bio Plc

TIDMMTFB

RNS Number : 7677S

Motif Bio PLC

10 July 2015

10 July 2015

Motif Bio Plc

(the "Company")

Result of General Meeting

Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that at the General Meeting held earlier today all resolutions as set out in the Notice of General Meeting annexed to the circular to shareholders dated 23 June 2015 were duly passed. The passing of the resolutions represents the satisfaction of the first of the two conditions to completion of the conditional placing of 44,000,000 ordinary shares announced by the Company on 23 June 2015.

The second condition, being the successful grant of the QIDP designation for iclaprim in the US (such grant not to be later than 24 July 2015), remains to be satisfied.

Enquiries:

 
 Motif Bio plc                                        info@motifbio.com 
  Graham Lumsden (Chief Executive Officer) 
  Robert Bertoldi (Chief Financial Officer) 
  www.motifbio.com 
 Zeus Capital Limited (NOMINATED ADVISER & JOINT 
  BROKER)                                             +44 (0) 207 
  Phil Walker/John Treacy/Dominic Wilson               183 5860 
 Northland Capital Partners Limited (JOINT BROKER) 
  Gerry Beaney/David Hignell                          +44 (0) 20 
  John Howes/Mark Treharne (Broking)                   7382 1100 
                                                      +44 (0) 207 
 Plumtree Capital Limited (FINANCIAL ADVISER)          183 2493 
 Stephen Austin 
                                                           +44 (0) 7768 
                                                                537 739 
 
 Yellow Jersey PR Limited (FINANCIAL PR) 
  Dominic Barretto/Philip Ranger/Fiona Walker 
                                                             +49 (0) 89 
  MC Services (TRADE PR)                                       210 2280 
  Raimund Gabriel                                           +44 (0) 207 
  Shaun Brown                                                  148 5998 
 

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMGGUQWMUPAGPU

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024